Navigation Links
Anesthesia Drugs Market in U.S. worth $7 Billion by 2015: MarketsandMarkets

DALLAS, May 17, 2012 /PRNewswire/ --

The "Anesthesia Drugs Market (2011 - 2015) - U.S. Market Entry Study" analyzes and studies the U.S. market for intravenous anesthesia drugs with special focus on ketamine, distribution structure of anesthesia drugs in U.S., potential buyers, export & import system for controlled substances in U.S. and U.S. market entry strategy.

Browse market data tables and in-depth TOC of "Anesthesia Drugs Market (2011 - 2015) - U.S.Market Entry Study". 

Early buyers will receive 10% customization on reports.

This report studies the U.S. Ketamine market over the period of 2007-2015. Ketamine market is expected to grow at a moderate rate from 2011 to 2016. Anesthesia is a condition in which sensation is totally or partially blocked. This enables the patients to undergo medical procedures and surgery. Based on the applications (type of surgery or medical procedure) anesthetic drugs are broadly categorized into two types; i.e. local anesthetic drugs and general anesthetic drugs. Local anesthesia is a condition when sensation within a specific body part in inhibited, where as general anesthesia results in loss of consciousness and sensation.

General anesthesia includes blockage of pain, awareness, and memory. Advantages offered by general anesthesia includes - rapid onset of anesthesia, full control of the body processes (airway, respiratory and circulatory system), used in surgeries with unpredictable duration of surgery, no memory of the surgery, allows complete motionlessness over prolonged duration of the surgery and it permits simultaneous operation on different body parts.

General anesthesia drugs involve inhalation and intravenous anesthesia drugs. Report is specially focused on general intravenous anesthesia drugs category. Drugs such as propofol, midazolam & diazepam, fospropofol disodium, sodium pentothal, ketamine, methohexital sodium, pentobarbital, etomidate, and fentanyl are studied.

The U.S. general anesthesia drugs market size was approximately $2 billion in 2011 and is expected to grow at a moderate rate, with a CAGR of approximately 4% from 2011 to 2015. In addition, intravenous anesthetic drugs accounted for the largest share -65% - of the U.S. general anesthetics drugs market in 2011.

Ketamine is an anesthetic drug mainly used for initiation and maintenance of general anesthesia in humans. It belongs to NMDA receptor antagonist class, which includes molecules that prevent the action of the N-methyl D-aspartate (NMDA) receptor. Factors such as increase in aging population, rising cardiovascular, and respiratory system related diseases and rising number of emergency surgeries will help in maintaining stable growth in the ketamine market revenue in the next five years along with the overall growth of the U.S. general intravenous anesthesia market.

About MarketsandMarkets

MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.

MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals; including advanced materials, automotives and transportation, banking and financial services, biotechnology, chemicals, consumer goods, energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals [ ], semiconductor and electronics and telecommunications and IT.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository. To know more about us and our reports, please visit our website

Mr. Rohan
North - Dominion Plaza,
17304 Preston Road,
Suite 800, Dallas, TX 75252
Tel: +1-888-6006-441
MarketsandMarkets Blog @

SOURCE MarketsandMarkets
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Susquehanna Health Selects Perioperative and Anesthesia Automation Solution from Surgical Information Systems
2. Dehaier Medical Systems Extends Product Offerings with Exclusive Distribution Agreement for Penlon Anesthesia System in North China
3. American Society of Anesthesiologists Primary Agenda Displayed Says Dr. Barry Friedberg of Cosmetic Surgery Anesthesia
4. LI-COR Biosciences and Euthanex Corporation Provide Anesthesia System for Small Animal Imaging
5. Researchers reveal why some pain drugs become less effective over time
6. Islet Sciences Announces DiaKine Therapeutics Novel Diabetes, Atherosclerosis Drugs Receives European Patent Protection
7. New drugs show promise for preventing absence seizures in children: UBC research
8. DFH Pharma to Collaborate With National Cancer Institute to Develop Second-Generation HIV Maturation Inhibitor Drugs
9. FDAs Oncologic Drugs Advisory Committee to Review Resubmitted Pixantrone New Drug Application on February 9, 2012
10. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
11. Malaria discovery gives hope for new drugs and vaccines
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... InSphero AG, the leading supplier of ... has promoted Melanie Aregger to serve as Chief Operating Officer. , Having ... management team and was promoted to Head of InSphero Diagnostics in 2014. ...
(Date:11/24/2015)... 24, 2015 HemoShear Therapeutics, LLC, a ... for metabolic disorders, announced today the appointment of ... of Directors (BOD). Mr. Watkins is the former ... Sciences (HGS), and also served as the chairman ... Powers , Chairman and CEO of HemoShear Therapeutics. ...
(Date:11/24/2015)... YORK , Nov. 24, 2015 According to ... than in 2005. This is something that many doctors, scientists, ... time. One questions remains: with fewer PSA tests being done, ... ? Dr. David Samadi, "Despite the ... the disease remains the second leading cancer cause of death ...
(Date:11/23/2015)... ... November 23, 2015 , ... ... development of its Nexera UC Unified Chromatography system. The award from R&D magazine ... new products of the year in the analytical and testing category. R&D Magazine ...
Breaking Biology Technology:
(Date:11/10/2015)... , Nov. 10, 2015 ... behavioral biometrics that helps to identify and verify ... Signature is considered as the secure and accurate ... identification of a particular individual because each individual,s ... accurate results especially when dynamic signature of an ...
(Date:11/2/2015)... Calif. , Nov. 2, 2015  SRI International ... million to provide preclinical development services to the National ... contract, SRI will provide scientific expertise, modern testing and ... variety of preclinical pharmacology and toxicology studies to evaluate ... --> The PREVENT Cancer Drug Development Program ...
(Date:10/29/2015)... ARBOR, Mich. , Oct. 29, 2015 /PRNewswire/ ... Eurofins Genomics for U.S. distribution of its DNA ... DNA-seq kit and Rubicon,s new ThruPLEX Plasma-seq kit. ... to enable the preparation of NGS libraries for ... plasma for diagnostic and prognostic applications in cancer ...
Breaking Biology News(10 mins):